Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD18m

    Last close

    AUD0.00

    ▲ 0.00 (100.00%)

    Verve Group

    MCap

    EUR652m

    Last close

    EUR3.50

    ▲ 0.54 (18.07%)

    OSE Immunotherapeutics

    MCap

    EUR193m

    Last close

    EUR8.84

    ▲ 0.69 (8.47%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 07/09/2024

1.32

▲ 0.04 (3.13%)

Market capitalisation

22m

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Healthcare | Flash note

Kazia Therapeutics — Reinvestment period with increased R&D focus

Healthcare | ADR Flash

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Healthcare | Update

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Healthcare | Flash note

Kazia Therapeutics — Q123 cash flows in line with our estimates
Visit Website

Balance Sheet

Forecast net debt (US$m)

6

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 28.2 (77.5)
Relative 3.2 19.1 (78.4)
52 week high/low US$6.0/US$0.5

Financials

Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and efficacy of paxalisib in non-central nervous system (CNS) oncology indications such as melanoma and other solid tumors, including breast cancer. Post-period, Kazia announced a A$4.5m fund-raise through a two-stage private placement of 40.9m new shares (25.4m unconditional shares and 15.5m conditional shares) at A$0.11 per share. Management intends to use the proceeds to support its development programs (including the paxalisib GBM AGILE study due to readout in H2 CY23) and working capital requirements. The period-end net cash balance stood at A$4.4m and this, along with the A$4.5m fund-raise, should provide headroom into H2 CY23, based on current burn rates.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.7 (3.1) (3.1) (25.09) N/A N/A
2022A 0.0 (14.9) (14.9) (110.57) N/A N/A
2023E 0.0 (19.0) (19.0) (111.41) N/A N/A
2024E 10.8 (17.2) (17.2) (82.84) N/A N/A

Research

Flash note

Healthcare

Kazia Therapeutics — Paxalisib receives ODD for AT/RT

ADR Update

Healthcare

Kazia Therapeutics — Deep dive into childhood brain cancer

Healthcare

edison tv

Kazia Therapeutics webinar – Combating childhood brain cancer

edison tv

Healthcare

EVT801, Kazia’s second programme, and capital markets

edison tv

Healthcare

Paxalisib: Beyond glioblastoma and commercial opportunity

edison tv

Healthcare

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

ADR Update

Healthcare

Kazia Therapeutics — Several upcoming catalysts

edison tv

Healthcare

Kazia Therapeutics: Edison Open House Healthcare 2022

edison tv

Healthcare

Kazia Therapeutics – introducing novel asset EVT-801

ADR Update

Healthcare

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Update

Healthcare

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

edison tv

Healthcare

Kazia Therapeutics – overview and update with CEO James Garner

ADR Update

Healthcare

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Update

Healthcare

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

ADR Update

Healthcare

Kazia Therapeutics — Paxalisib Chinese rights licensed

Update

Healthcare

Kazia Therapeutics — Paxalisib Chinese rights licensed

ADR Update

Healthcare

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Update

Healthcare

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

edison tv

Healthcare

Kazia Therapeutics – Edison Open House interview

ADR Update

Healthcare

Kazia Therapeutics — Cantrixil final Phase I data reported

Update

Healthcare

Kazia Therapeutics — Cantrixil final Phase I data reported

ADR Update

Healthcare

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Update

Healthcare

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Initiation

Healthcare

Kazia Therapeutics — Bringing a vetted drug class to the brain

Update

Healthcare

Kazia Therapeutics — Paxalisib trial still on track for H220 start

ADR Update

Healthcare

Kazia Therapeutics — An agile pivot

Update

Healthcare

Kazia Therapeutics — An agile pivot

ADR Update

Healthcare

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

edison tv

Healthcare

Executive interview – Kazia Therapeutics

Update

Healthcare

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Update

Healthcare

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

ADR Outlook

Healthcare

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Outlook

Healthcare

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

ADR Update

Healthcare

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Update

Healthcare

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

ADR Update

Healthcare

Kazia Therapeutics — New indications for GDC-0084

Update

Healthcare

Kazia Therapeutics — New indications for GDC-0084

ADR Update

Healthcare

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Update

Healthcare

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Outlook

Healthcare

Kazia Therapeutics — GDC-0084 Phase II underway

ADR Outlook

Healthcare

Kazia Therapeutics — GDC-0084 Phase II underway

Update

Healthcare

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Update

Healthcare

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Outlook

Healthcare

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Outlook

Healthcare

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Update

Healthcare

Novogen — Update 31 October 2016

ADR Update

Healthcare

Novogen — Update 11 May 2016

Update

Healthcare

Novogen — Update 9 May 2016

thematic

Consumer

ConsumerWatch – The times they are a-changin’

thematic

Investment Companies

Emerging markets – Worthy of consideration

thematic

Investment Companies

Dynam Capital at the 2024 Vietnam ESG Conference

thematic

TMT

MediaWatch – Glimpses of positivity

thematic

Consumer

ConsumerWatch – Give me a reason to love you

thematic

Investment Companies

UK stock market – Scope for further upside in UK large-cap stocks

thematic

Investment Companies

Listed private equity – Performing a balancing act

thematic

Consumer

ConsumerWatch – At least someone loves me

thematic

TMT

MediaWatch – Rinse and repeat

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Financials

South African life assurers: Where is the growth?

thematic

Consumer

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

thematic

TMT

Deutsches Eigenkapitalforum (EKF) 2023 technology

thematic

Financials

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

thematic

Industrials

Deutsches Eigenkapitalforum (EKF) 2023 industrials

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

TMT

MediaWatch – Still waiting…

thematic

Consumer

ConsumerWatch – Falling into the fall

thematic

Metals & Mining

Shades of the 1970s

thematic

Industrials

The long and winding road

thematic

TMT

MediaWatch – Targeting the opportunities

thematic

Consumer

ConsumerWatch – Making the most of the summer

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Financials

IFRS 17: Impact on life assurance companies

thematic

TMT

MediaWatch – Vision On

thematic

Consumer

ConsumerWatch – A Spring in the step

thematic

Industrials

Quantum computing: A booming industry

thematic

Metals & Mining

Critical minerals: The investment vacuum

thematic

Financials

Crypto, are you dead yet?

thematic

Industrials

UK housebuilders

thematic

Investment Companies

European equities

thematic

Investment Companies

Listed Private Equity
samuel-scrimshaw-kp_87tExCwI-unsplash

thematic

Metals & Mining

Lithium’s adolescence
Concept of energy storage unit consisting of multiple conected containers with batteries. 3d rednering.

thematic

Industrials

Battery energy storage
Digital Marketing and Internet Media Technology Platform

thematic

TMT

MediaWatch – Screening well

thematic

Investment Companies

Vietnamese equities: Due a comeback?

thematic

Healthcare

Machine learning in drug development

thematic

Consumer

ConsumerWatch – January sales

thematic

Healthcare

Outlook for 2023: Biotechs remain central to novel drug development
Cancer cells

thematic

Healthcare

Oncology ABCs (part four): Blood cancers (AML) – notable innovations
cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Investment Companies

Investment companies: Latin America is worthy of consideration

thematic

Healthcare

Drug delivery platforms

thematic

Real Estate

South African industrial property fundamentals are strong

thematic

Metals & Mining

Lepidico: Offer closes, oversubscribed

thematic

Healthcare

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

UK motor P&C insurers series

thematic

Healthcare

Neuroscience comeback

thematic

Real Estate

South African retail property funds remain resilient

thematic

Consumer

ConsumerWatch – Bargains galore

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

Consumer

Food tech – At the forefront of food innovation

thematic

TMT

ESG, moving beyond the box tick

thematic

Consumer

ConsumerWatch – Value emerging

thematic

Healthcare

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Industrials

A new paradigm for space

thematic

Geopolitical conflict to drive renewables surge

thematic

Industrials

The emergence of mega-constellations

thematic

Industrials

Internet in the sky

thematic

Global markets: Valuation ‘normalisation’ continues

thematic

Financials

Revisiting IPOs in London

thematic

TMT

Direct tech investors

thematic

Investment Companies

The case for US capital markets

thematic

Industrials

Truth creates light

thematic

Industrials

All-seeing eye in the sky

thematic

Metals & Mining

Five (more) things every investor should know about lithium and Lepidico

thematic

Healthcare

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Seven things every investor needs to know about SenSen

thematic

The industrialisation of space

thematic

Five things every investor should know about everyday decarbonisation and Itaconix

thematic

Feeding the world

thematic

Global strategic insight: Still neutral on global equities, with caveats

thematic

Consumer

Circular economy business models

thematic

Metals & Mining

Decarbonisation – A potential opportunity for aluminium producers

thematic

Seven things every investor should know about Unbound Group

thematic

Five things you need to know about AQRU and crypto 2.0

thematic

Global strategic insight: Putin’s invasion – turning back now

thematic

Global perspectives: Investment implications of Putin’s invasion

thematic

Consumer

Moving from a vegan January to a sustainable one

thematic

Industrials

BayWa – Focus on sustainability

thematic

Global perspectives: Earnings momentum still positive

thematic

Consumer

Cultivated meat – Engineering the growth of alternative meats

thematic

Metals & Mining

The PGM markets – Outlook and price forecasts

thematic

Have yourself a sustainable little Christmas

thematic

Global perspectives – Omicron: A 2-week waiting game

thematic

COP26: What does it mean for business?

thematic

Equity strategy and market outlook – November 2021

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Industrials

Investment themes: IPO boom in London

thematic

Demand for Teslas points to lithium deficit

thematic

COP26: No matter the outcome, the private sector is the engine of change

thematic

Equity strategy and market outlook – October 2021

thematic

COP26: Time to realign your supply chain with net-zero goals?

thematic

Global Perspectives: Remaining cautious as risks surface

thematic

Equity strategy and market outlook – September 2021

thematic

TMT

Quantum dots – all the colours of the rainbow

thematic

Global perspectives: Moving to a cautious outlook

thematic

Laser diodes – may the force be with you

thematic

TMT

Micro-LEDs – small is beautiful

thematic

Caution – slowdown ahead

thematic

The five key ESG themes investors are asking about now

thematic

Consumer

The future of fish – The investment case for sustainable fishing

thematic

Equity strategy and market outlook – August 2021

thematic

The growth of UK food ordering and delivery platform

thematic

Financials

Bitcoin’s investment thesis – How ‘dirty’ is the Bitcoin network’s carbon footprint?

thematic

Global perspectives: Valuations in the ointment

thematic

Equity strategy and market outlook – July 2021

thematic

Energy & Resources

Finding the sea of green – The opportunity and options for shipping green H2

thematic

Healthcare

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Global equities: Volatility rises at the upper reaches of valuation

thematic

Five things every investor needs to know about Mynaric

thematic

Global perspectives: Growth wobble unnerves markets – can UK keep delta in check?

thematic

Equity strategy and market outlook – June 2021

thematic

Five key takeaways from the Edison Open House Future of Transportation 2021

thematic

Global perspectives: Sitting still can be hard to do

thematic

Equity strategy and market outlook – May 2021

thematic

Industrials

The circular economy

thematic

Equity strategy and market outlook – April 2021

thematic

Energy & Resources

Decarbonisation

thematic

Industrials

EV outlook #1 – Growth, policy and net zero

thematic

Reasons to be cheerful – UK leisure ready and waiting

thematic

Equity strategy and market outlook – March 2021

thematic

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Global perspectives: Rising US bond yields? Value investors have little to fear

thematic

Real Estate

South African listed property sector

thematic

South African life assurance – Potential capital release boost

thematic

Global perspectives UK: The value of vaccination

thematic

Equity strategy and market outlook – February 2021

thematic

Healthcare

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Equity strategy and market outlook – January 2021

thematic

Equity valuations matter when framed in the right context

thematic

Global perspectives: Profits forecasts robust as COVID-19 rages

thematic

ESG investing

thematic

Investment Companies

Value Investing: Living with the reality, waiting for the inevitable

thematic

Equity strategy and market outlook – November 2020

thematic

Virtual conferences are amazing. But can we get back together soon?

thematic

An even more momentous trend – Brilliance overcomes darkness

thematic

Equity strategy and market outlook – October 2020

thematic

Consumer

Meating Demand – The lean, green money-making machine

thematic

Global Perspectives: US election – Trump OK, Biden OK but neither not OK.

thematic

Global perspectives – Cyclicals recovery building a head of steam

thematic

Equity strategy and market outlook – September 2020

thematic

After the storm: Earnings estimates stabilise

thematic

Equity strategy and market outlook – August 2020

thematic

Illuminator – August Update

thematic

TMT

Semiconductor winners – European companies with strong positions

thematic

Equity strategy and market outlook – July 2020

thematic

Global perspectives – Global growth stocks over-hyped in 2020?

thematic

Short Monitor – Hammerson most shorted UK stock

thematic

Illuminator – July Update

thematic

Global perspectives: Still neutral on equities, but uncertainty reigns

thematic

Global perspectives: Markets cut to the chase – should you?

thematic

Equity strategy and market outlook – June 2020

thematic

TMT

The small satellite market – Small is beautiful

thematic

Global perspectives: Inject a note of caution into asset allocations

thematic

Equity strategy and market outlook – May 2020

thematic

Global perspectives: The biggest recession since the Great Depression

thematic

Global perspectives: Between a lockdown and a hard place

thematic

Equity strategy and market outlook – April 2020

thematic

Global perspectives: Past the first inflection point in consensus earnings estimates

thematic

TMT

European video games: A safe haven in troubled times

thematic

Global perspectives: Difficult headlines, discounted markets

thematic

Illuminator – March Update

thematic

Global perspectives: The time to panic has passed

thematic

Edison Exhibits- A bull market for precious metals

thematic

Equity strategy and market outlook – February 2020

thematic

TMT

Blockchain adoption: Implications for the financial services sector

thematic

decline on coronavirus impact

thematic

Lighthouse – An ESG Centred Week

thematic

Illuminator – February Update

thematic

Equity strategy and market outlook – January 2020

thematic

Coronavirus: Markets wake-up to the risks

thematic

Edison Exhibits – 2020: Fearful of missing out?

thematic

Illuminator – January Update

thematic

Industrials

Battery charge: The rise of lithium-ion – options and implications

thematic

UK election – If the polls are right, UK risk premium set to fall

thematic

Equity strategy and market outlook – November 2019

thematic

Mega-cap equities still priced to outperform bonds

thematic

Illuminator – November Update

thematic

Earnings forecasts: 2019

thematic

Short monitor- Fluttering uncertainty and trade unions

thematic

Equity strategy and market outlook – October 2019

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Past the peak of political risk?

thematic

Industrials

Water – The real liquidity crisis

thematic

Illuminator – October Update

thematic

Industrials

Greece – Changing the narrative

thematic

Brexit – Through the fog of war on public opinion

thematic

Moving to a neutral position on global equities

thematic

Illuminator: September Update

thematic

Equity strategy and market outlook – August 2019

thematic

Consumer

Illuminator: August Update

thematic

Staying focused on the facts – the risks remain in place

thematic

Investment Companies

Post Woodford- A spotlight on smaller company liquidity

thematic

TMT

European video games

thematic

Equity strategy and market outlook – July 2019

thematic

Healthcare

The next wave in AMD

thematic

2019 earnings forecasts back on a declining trend

thematic

Illuminator: July Update

thematic

TMT

Diversification and scale for online success

thematic

Financials

IFRS 16

thematic

Equity strategy and market outlook – June 2019

thematic

Liquidity

thematic

Financials

DACH Industrial & Logistic Property

thematic

2019 earnings forecasts losing momentum

thematic

Minimal capitulation from the FOMC

thematic

Whatever it takes… all over again!

thematic

Healthcare

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Could the US Fed be enabling a continuation of the trade war?

thematic

Investment Companies

How to buy and sell investment trusts

thematic

Equity strategy and market outlook – May 2019

thematic

The value of a shareholder register

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Shifting trade politics should not be ignored

thematic

Metals & Mining

Alliance Mineral Assets secures strategic investment from Galaxy and Jiangxi

thematic

Financials

Time value of money

thematic

TMT

5G – Strategic importance, but lacking a near-term commercial driver

thematic

A risk-on environment is a good time to take risk off

thematic

ECB: Next ECB President must keep up the pace of change

thematic

Metals & Mining

Piedmont Lithium increases its mineral resource estimate by 21%

thematic

Equity strategy and market outlook – April 2019

thematic

Financials

Cash flow

thematic

Stronger survey data quashes recession fears for now

thematic

Healthcare

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Industrial Automation

thematic

Energy & Resources

Verbier appraisal points to lower than expected resources

thematic

Equity strategy and market outlook – March 2019

thematic

Yield curve a US recession signal? Maybe not this time

thematic

Investment Companies

Types of investment trusts

thematic

Brexit: EU can do it if you really want…

thematic

Energy & Resources

Orinduik resource upgrade for Eco Atlantic offshore Guyana

thematic

Brexit: PM May’s deal may finally be in sight

thematic

Energy & Resources

No moveable hydrocarbons in Alaskan Winx-1 well

thematic

Energy & Resources

Hydrocarbon discovery for Murphy at Cholula-1 offshore Mexico

thematic

Brexit: The big guns go silent

thematic

ECB: Buy the rumour, sell the news

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Equity strategy and market outlook – February 2019

thematic

UK video games – Heterogeneous not homogeneous

thematic

TMT

UK video games – Heterogeneous not homogeneous

thematic

Market outlook: balanced but still biased to upside

thematic

Financials

Enterprise versus equity valuation

thematic

Healthcare

The diagnostics sector

thematic

ECB fiddles as eurozone turns

thematic

Metals & Mining

Gold stars and black holes

thematic

Financials

Deutsche Börse’s Scale

thematic

Financials

Price to earnings ratio

thematic

FOMC: US Fed merely matches expectations

thematic

Brexit: Prepare for a confrontation

thematic

Brexit on pause as UK PM challenged

thematic

Economic survey data on a weakening trend outside US

thematic

Energy & Resources

Sound Energy well result highlights reservoir variability in Morocco

thematic

Brexit: A decisive step into the fog

thematic

2019 Earnings forecasts softening

thematic

Market valuations improving in UK and Europe

thematic

Rising US bond yields spark volatility breakout

thematic

Energy & Resources

Tullow’s Namibian well disappoints

thematic

Brexit: UK Risk premium likely to remain in place

thematic

2018 Earnings forecasts stable over the summer

thematic

Choose your narrative with care for 2019

thematic

Energy & Resources

Tullow spuds Cormorant well offshore Namibia

thematic

Energy & Resources

Southern gas corridor to the EU nears agreement

thematic

Turkey:When risks collide

thematic

Energy & Resources

Mexico: reassurance or uncertainty?

thematic

Earnings estimates: Marginal declines could point to trouble ahead

thematic

The post-ASCO IO pecking order

thematic

The post-ASCO IO pecking order

thematic

The post-ASCO IO pecking order

thematic

Earnings revisions: No sign of a trade war (yet)

thematic

Guaranteed security? Investment implications of US foreign policy

thematic

Global implications of rising US yields